strong pipelin near-term
catalyst upgrad buy
adjust ep exclud non-cash one-tim item
headquart wilmington de biotechnolog compani develop drug treat cancer
provid overview inci pipelin detail analysi fgfr gvhd program
fgfr new jak pemigatinib fgfr inhibitor one import asset target therapi
cholangiocarcinoma bile duct cancer demonstr overal respons rate orr complet
respons cr rate patient show month median progress free surviv month
median overal surviv os plan file new drug applic nda indic also
potenti treat tumor type includ bladder cancer estim peak sale pemigatinib
cholangiocarcinoma bladder cancer combin
gvhd blockbust indic besid jakafi potenti approv steroid refractor gvhd acut
set nda see blockbust potenti fully-own itacitinib target nave gvhd compani
expect result itacitinib phiii steroid nave acut gvhd estim peak sale
upgrad buy due increas valu pipelin multipl catalyst past two
month observ acquir increas interest revenue-gener oncolog asset includ gsk-tsro
bmy-celg lly-loxo total tabl believ valuabl mid-cap oncolog asset
larg pharma buyer calcul pmv estim per share margin safeti
valuat support sum-of-the-part analysi key product peak sale multipl tabl
valuat sale multipl
exclud non-cash one-tim item beyond
assetphas valuat multipl jakafi royalti iclusig baricitinib royalti itacitinib pipelin total sale adjust clinic risk multipl adjust clinic risk research estim sales/ sale billion valuat billion fiscal year end million except per share cont op multipl
fgfr jak pemigatinib fgfr inhibitor current phase cholangiocarcinoma
bile duct cancer bladder cancer
cholangiocarcinoma bile duct cancer rare tumor type approxim patient us eu
japan fgfr alter exhibit often diagnos late stage therefor prognosi
usual poor overal respons rate orr first-lin chemotherapi approxim
month overal surviv os second-lin orr chemo low median
progress free surviv month
phase ii studi cholangiocarcinoma pemigatinib achiev orr patient
cohort benefit low fgfr fgfr cohort demonstr month median
month median os plan file new drug applic nda indic
compani also plan start phase set also expect see improv
standard care
fgfr patient incid tumor type
pemigatinib also potenti treat bladder cancer fgfr much larger indic
patient us eu japan drug demonstr orr patient intermitt
dose week week ad anoth cohort continu dose similar competitor
erdafitinib trial data expect anticip respons rate improv
cohort compani like file snda bladder pemigatinib also potenti treat
indic fgfr exhibit
fgfr expect competit market exhibit file nda fgfr inhibitor erdafitinib
bladder cancer phase continu dose demonstr orr month
month os patient compani fell behind develop fgfr inhibitor
oncolog yet late-stag data expect take major market share
indic estim market bladder cancer cholangiocarcinoma billion
pemigatinib peak sale million indic combin
gvhd blockbust indic graft-versus-host diseas gvhd common sever complic
develop post allogeneic/donor stem cell transplant donor cell graft attack patient healthi
tissu organ host approxim transplant patient develop gvhd affect
patient us eu japan exhibit half gvhd patient develop acut form
usual occur within day post-transpl steroid wide use first-lin treatment
achiev respons rate sever acut gvhd poor prognosi patient one year surviv
rate sever chronic gvhd develop chronic patient overal surviv
time two year post-transpl
gvhd incid rate
incyt comprehens gvhd program includ jakafi steroid refractori gvhd itacitinib
steroid nave gvhd exhibit jakafi demonstr rapid durabl respons
orr cr patient compani file snda acut gvhd pdufa
date februari jakafi alreadi use off-label gvhd physician
meanwhil half target physician experi prescrib jakafi approv
indic compani file chronic use separ data readout estim
us sale jakafi gvhd novarti ex-u commerci right
believ jakafi competit safeti profil compar imbruvica drug approv
chronic gvhd achiev orr cr patient phase jakafi treatment-
relat death phase compar two death report patient phase imbruvica along
discontinu rate importantli jakafi abl reduc steroid dose among
patient phase imbruvica current test gvhd phase gvhd
drug early-stag develop believ competit
besid jakafi potenti approv gvhd see blockbust potenti fully-own itacitinib
first-lin steroid-nav gvhd patient us eu japan doubl
early-stag studi acut gvhd itacitinib demonstr orr cr patient
averag two month treatment phase studi itacitinib acut gvhd
expect read phase itacitinib chronic gvhd start
enrol patient estim itacitinib peak sale expect higher penetr rate
market share jakafi due high respons rate limit competit
tabl sale sale multipl select biotech transact
million except per multipl privat market total minu convert minu option payment equiti privat market share outstand pmv per current market discount after-tax payment buy option convert holder privat market valu sourc compani report research estim billion dateaquirertargetasset/diseasepeak salesjan lillyloxo oncolog vitrakvi xn/a n/a bristol-my squibbcelgen revlimid zejula takedashirerar novartisavexisgen n/a n/ajan sanofiablynxrar blood bioverativhemophilia celgenejuno car-t kitecar-t n/a n/ajul merck astrazenecalynparza jnjactelionrar astellasosi close yetsourc compani report research estim deal valuedeal/peak ltm sale deal/ltm sale
jing research analyst prepar report herebi certifi view express report accur reflect analyst
person view subject compani secur research analyst receiv direct
indirect compens express specif recommend view report
public data april buy recommend
chang hold april
